San Mateo, California-based Route 92 develops a suite of reperfusion and access systems leveraging the patented Tenzing delivery catheter. The products aim to improve the efficiency of endovascular thrombectomy procedures. The company designed its technology to enable the quick restoration of blood flow to the brain following acute ischemic stroke.
The company alleges that Q’Apel infringes on five patents protecting the Tenzing delivery catheter. Tenzing currently has 23 U.S. patents protecting it, according to a news release. It filed the complaint today, Oct. 7, 2024, in the United States District Court for the District of Delaware.
Route 92 says its “continued innovation depends upon its ability to protect its products globally. Its neurovascular portfolio features the FreeClimb 70 and FreeClimb 54 reperfusion systems. Additionally, the company offers the FreeClimb 88 catheter system and has an ongoing clinical study evaluating its HiPoint 88 and HiPoint 70 reperfusion catheters as part of the Monopoint reperfusion system.
The company last month added $50 million in financing to support these technologies.
“Route 92 Medical has reinvented neurovascular intervention. Our growing sales are a testament to the superiority of our solutions,” said Tony Chou, CEO. “In light of our success, it’s not surprising that other companies have looked for ways to emulate the customer-preferred features of the Tenzing delivery catheter and other Route 92 Medical products. Yet, with more than 100 patents protecting our innovations worldwide, we want to make clear that we will vigorously defend our intellectual property.”
